PE20040780A1 - Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion - Google Patents
Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacionInfo
- Publication number
- PE20040780A1 PE20040780A1 PE2003001078A PE2003001078A PE20040780A1 PE 20040780 A1 PE20040780 A1 PE 20040780A1 PE 2003001078 A PE2003001078 A PE 2003001078A PE 2003001078 A PE2003001078 A PE 2003001078A PE 20040780 A1 PE20040780 A1 PE 20040780A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- piperidin
- oxo
- substituted
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 title 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 title 1
- -1 IMINO Chemical class 0.000 abstract 5
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 abstract 1
- 102100037189 Sodium- and chloride-dependent transporter XTRP3 Human genes 0.000 abstract 1
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical class [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 abstract 1
- 150000003973 alkyl amines Chemical class 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003574 free electron Substances 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Abstract
SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA I DONDE A ES O o S, FENILSULFONILAMINO O CIANIMINO; X ES O o S, IMINO EVENTUALMENTE SUSTITUIDO CON ALQUILO C1-C6, ENTRE OTROS; Y y Z SON ALQUILO C1-C6 LINEAL O RAMIFICADO, SUSTITUIDO O NO CON F, PUDIENDO FORMAR DICHOS GRUPOS ALQUILO, JUNTO AL CARBONO AL QUE ESTAN UNIDOS, UN ANILLO DE 4-8 MIEMBROS; R1 ES UN HETEROCICLO AZA, DIAZA, ENTRE OTROS; R2 ES H, FENILMETILO, ALQUILO C2-C7, QUE EN POSICION w PUEDE ESTAR SUSTITUIDO POR CICLOHEXILO, FENILO, ENTRE OTROS; R3 ES H, ALQUILO C1-C3 SUSTITUIDO O NO CON FENILO O PIRIDINILO; R2 Y R3 JUNTO CON EL N AL QUE ESTAN UNIDOS FORMAN UN RADICAL DE FORMULA II, EN DONDE Y1 ES C o CUANDO R5 REPRESENTA UN PAR DE ELECTRONES LIBRES, TAMBIEN PUEDE SER N; q Y r, CUANDO Y1 ES C, ES 0, 1 o 2, o CUANDO Y1 ES N, ES 1 o 2; R4 ES H, AMINO, ALQUILAMINO, ENTRE OTROS; R5 ES H, ALQUILO C1-C4; R6 Y R7 SON H, ALQUILO C1-C3, DIALQUILO C1-C3-AMINO, O CUANDO Y1 NO ES N PUEDE SER F; R8 Y R9 SON H o ALQUILO C1-C3. SON COMPUESTOS PREFERIDOS: {(R)-1-(3,4-DIETIL-BENCIL)-2-[4-(1-METIL-PIPERIDIN-4-IL)-PIPERAZIN-1-IL]-2-OXO-ETIL}-AMIDA DE ACIDO 4-(2-OXO-1,2,4,5-TETRAHIDRO-1,3-BENZODIAZEPIN-3-IL)-PIPERIDIN-1-CARBOXILICO; {(R)-1-(3,4-DIETIL-BENCIL)-2-[4-(4-METIL-PIPERAZIN-1-IL)-PIPERIDIN-1-IL]-2-OXO-ETIL}-AMIDA DE ACIDO 4-(2-OXO-1,2,4,5-TETRAHIDRO-1,3-BENZODIAZEPIN-3-IL)-PIPERIDIN-1-CARBOXILICO; TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON ANTAGONISTAS DE GCRP
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10250082A DE10250082A1 (de) | 2002-10-25 | 2002-10-25 | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20040780A1 true PE20040780A1 (es) | 2005-01-14 |
Family
ID=32103088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003001078A PE20040780A1 (es) | 2002-10-25 | 2003-10-23 | Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion |
Country Status (25)
Country | Link |
---|---|
US (3) | US20040132716A1 (es) |
EP (1) | EP1558601A1 (es) |
JP (1) | JP4435687B2 (es) |
KR (1) | KR20050083821A (es) |
CN (1) | CN1708492A (es) |
AR (1) | AR043056A1 (es) |
AU (1) | AU2003276157A1 (es) |
BR (1) | BR0315642A (es) |
CA (1) | CA2503462A1 (es) |
CO (1) | CO5570703A2 (es) |
DE (1) | DE10250082A1 (es) |
EA (1) | EA009984B1 (es) |
EC (1) | ECSP055746A (es) |
HR (1) | HRP20050365A2 (es) |
ME (1) | MEP51408A (es) |
MX (1) | MXPA05004188A (es) |
NO (1) | NO20052493L (es) |
PE (1) | PE20040780A1 (es) |
PL (1) | PL376373A1 (es) |
RS (1) | RS20050329A (es) |
TW (1) | TW200427681A (es) |
UA (1) | UA82206C2 (es) |
UY (1) | UY28040A1 (es) |
WO (1) | WO2004037811A1 (es) |
ZA (1) | ZA200502247B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10163595A1 (de) * | 2001-12-21 | 2003-08-07 | Gruenenthal Gmbh | In 3-Position heterocyclisch substituierte Piperidin-2,6-dione |
US7220862B2 (en) * | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
US7842808B2 (en) * | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
KR20120004541A (ko) * | 2002-06-05 | 2012-01-12 | 브리스톨-마이어스 스큅 컴퍼니 | 칼시토닌 유전자 관련 펩티드 수용체 길항제 |
US7595312B2 (en) * | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
US7569578B2 (en) * | 2003-12-05 | 2009-08-04 | Bristol-Meyers Squibb Company | Heterocyclic anti-migraine agents |
DE102004015723A1 (de) * | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
US20050282857A1 (en) * | 2004-04-15 | 2005-12-22 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102004018795A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7696195B2 (en) | 2004-04-22 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
US20050267141A1 (en) * | 2004-05-28 | 2005-12-01 | Phytogen Life Sciences Inc. | Process to prepare camptothecin derivatives |
US7659264B2 (en) * | 2004-10-07 | 2010-02-09 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
DE602005027870D1 (de) * | 2004-10-14 | 2011-06-16 | Merck Sharp & Dohme | Cgrp-rezeptorantagonisten |
US7745427B2 (en) * | 2004-10-22 | 2010-06-29 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7384931B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7449586B2 (en) * | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
DE102004063753A1 (de) * | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
DE102004063755A1 (de) * | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
DE102004063752A1 (de) * | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen |
CN101146799A (zh) * | 2005-03-23 | 2008-03-19 | 贝林格尔·英格海姆国际有限公司 | Cgrp拮抗剂、其制备方法以及其作为药物的用途 |
EP1770091A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7491717B2 (en) * | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
US7439237B2 (en) * | 2005-04-15 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102005038831A1 (de) * | 2005-08-17 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7834007B2 (en) * | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
EP1770086A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102005050892A1 (de) | 2005-10-21 | 2007-04-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
EP3069731A1 (en) | 2005-11-14 | 2016-09-21 | Labrys Biologics Inc. | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
DE102006017827A1 (de) * | 2006-04-13 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue kristalline Verbindungen |
PE20080153A1 (es) * | 2006-06-08 | 2008-04-14 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp) |
JP5335228B2 (ja) * | 2006-12-27 | 2013-11-06 | キヤノン株式会社 | 新規化合物および有機半導体素子の製造方法 |
KR20100091972A (ko) | 2007-10-18 | 2010-08-19 | 베링거 인겔하임 인터내셔날 게엠베하 | Cgrp 길항제 |
EP2065381A1 (de) | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP Antagonisten |
EP2251338A3 (de) | 2007-11-22 | 2011-06-08 | Boehringer Ingelheim International GmbH | Organische Verbindungen |
JP5745861B2 (ja) | 2008-03-04 | 2015-07-08 | ファイザー・リミテッドPfizer Limited | 炎症性疼痛を治療する方法 |
US8293239B2 (en) | 2008-03-04 | 2012-10-23 | Pfizer Limited | Methods of treating chronic pain |
BR112012004464B8 (pt) | 2009-08-28 | 2021-05-25 | Labrys Biologics Inc | uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica |
CA3048709A1 (en) | 2011-05-20 | 2012-11-29 | Alderbio Holdings Llc | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
SG194974A1 (en) | 2011-05-20 | 2013-12-30 | Alderbio Holdings Llc | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
HUE055505T2 (hu) | 2011-05-20 | 2021-11-29 | H Lundbeck As | Anti-CGRP készítmények és alkalmazásuk |
JPWO2016199688A1 (ja) * | 2015-06-10 | 2018-03-29 | 住友化学株式会社 | カーバメート化合物の製造方法 |
GB201519196D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
CR20210373A (es) | 2019-01-08 | 2021-08-19 | H Lundbeck As | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US665378A (en) * | 1900-06-15 | 1901-01-01 | William James Mcmurtry | Manufacture of self-igniting gas mediums. |
TW209870B (es) * | 1990-01-18 | 1993-07-21 | Pfizer | |
US5442044A (en) * | 1991-01-04 | 1995-08-15 | Pfizer Inc. | Orally active renin inhibitors |
ID21045A (id) * | 1996-09-10 | 1999-04-08 | Thomae Gmbh Dr K | Asam amino termodifikasi, obat-obatan yang mengandung senyawa ini dan proses pembuatannya |
DE19911039A1 (de) * | 1999-03-12 | 2000-09-14 | Boehringer Ingelheim Pharma | Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US6653478B2 (en) | 2000-10-27 | 2003-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators |
KR20120004541A (ko) * | 2002-06-05 | 2012-01-12 | 브리스톨-마이어스 스큅 컴퍼니 | 칼시토닌 유전자 관련 펩티드 수용체 길항제 |
DE10300973A1 (de) * | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
EP1722792A1 (de) | 2004-03-03 | 2006-11-22 | Boehringer Ingelheim International GmbH | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7547694B2 (en) | 2004-04-15 | 2009-06-16 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102004018794A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7279471B2 (en) | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102004018795A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7696195B2 (en) | 2004-04-22 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102004019492A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
CN101146799A (zh) | 2005-03-23 | 2008-03-19 | 贝林格尔·英格海姆国际有限公司 | Cgrp拮抗剂、其制备方法以及其作为药物的用途 |
EP1770091A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7491717B2 (en) | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
US7439237B2 (en) | 2005-04-15 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102005038831A1 (de) | 2005-08-17 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
EP1770087A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
EP1770086A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102005050892A1 (de) | 2005-10-21 | 2007-04-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
-
2002
- 2002-10-25 DE DE10250082A patent/DE10250082A1/de not_active Withdrawn
-
2003
- 2003-10-15 US US10/685,921 patent/US20040132716A1/en not_active Abandoned
- 2003-10-23 CA CA002503462A patent/CA2503462A1/en not_active Abandoned
- 2003-10-23 ME MEP-514/08A patent/MEP51408A/xx unknown
- 2003-10-23 CN CNA2003801019804A patent/CN1708492A/zh active Pending
- 2003-10-23 RS YUP-2005/0329A patent/RS20050329A/sr unknown
- 2003-10-23 BR BR0315642-7A patent/BR0315642A/pt not_active Expired - Fee Related
- 2003-10-23 JP JP2004545964A patent/JP4435687B2/ja not_active Expired - Fee Related
- 2003-10-23 PL PL03376373A patent/PL376373A1/xx not_active Application Discontinuation
- 2003-10-23 KR KR1020057007157A patent/KR20050083821A/ko not_active Application Discontinuation
- 2003-10-23 WO PCT/EP2003/011763 patent/WO2004037811A1/de active Application Filing
- 2003-10-23 MX MXPA05004188A patent/MXPA05004188A/es unknown
- 2003-10-23 UA UAA200504875A patent/UA82206C2/uk unknown
- 2003-10-23 AU AU2003276157A patent/AU2003276157A1/en not_active Abandoned
- 2003-10-23 PE PE2003001078A patent/PE20040780A1/es not_active Application Discontinuation
- 2003-10-23 EA EA200500601A patent/EA009984B1/ru not_active IP Right Cessation
- 2003-10-23 EP EP03809318A patent/EP1558601A1/de not_active Withdrawn
- 2003-10-24 TW TW092129585A patent/TW200427681A/zh unknown
- 2003-10-24 AR ARP030103890A patent/AR043056A1/es not_active Suspension/Interruption
- 2003-10-24 UY UY28040A patent/UY28040A1/es not_active Application Discontinuation
-
2005
- 2005-03-17 ZA ZA200502247A patent/ZA200502247B/xx unknown
- 2005-04-22 HR HR20050365A patent/HRP20050365A2/hr not_active Application Discontinuation
- 2005-04-25 EC EC2005005746A patent/ECSP055746A/es unknown
- 2005-05-24 CO CO05050510A patent/CO5570703A2/es not_active Application Discontinuation
- 2005-05-24 NO NO20052493A patent/NO20052493L/no not_active Application Discontinuation
-
2007
- 2007-06-04 US US11/757,743 patent/US7700589B2/en not_active Expired - Lifetime
-
2010
- 2010-02-17 US US12/706,840 patent/US20100152171A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW200427681A (en) | 2004-12-16 |
MXPA05004188A (es) | 2005-10-05 |
WO2004037811A8 (de) | 2005-05-19 |
US7700589B2 (en) | 2010-04-20 |
US20100152171A1 (en) | 2010-06-17 |
UA82206C2 (uk) | 2008-03-25 |
HRP20050365A2 (en) | 2006-05-31 |
BR0315642A (pt) | 2005-08-30 |
CA2503462A1 (en) | 2004-05-06 |
US20040132716A1 (en) | 2004-07-08 |
PL376373A1 (en) | 2005-12-27 |
JP4435687B2 (ja) | 2010-03-24 |
KR20050083821A (ko) | 2005-08-26 |
DE10250082A1 (de) | 2004-05-13 |
EA009984B1 (ru) | 2008-04-28 |
ECSP055746A (es) | 2005-07-06 |
NO20052493D0 (no) | 2005-05-24 |
ZA200502247B (en) | 2005-09-19 |
EA200500601A1 (ru) | 2006-02-24 |
NO20052493L (no) | 2005-05-24 |
WO2004037811A1 (de) | 2004-05-06 |
UY28040A1 (es) | 2004-05-31 |
EP1558601A1 (de) | 2005-08-03 |
AR043056A1 (es) | 2005-07-13 |
JP2006505573A (ja) | 2006-02-16 |
CO5570703A2 (es) | 2005-10-31 |
CN1708492A (zh) | 2005-12-14 |
RS20050329A (en) | 2007-08-03 |
AU2003276157A1 (en) | 2004-05-13 |
MEP51408A (en) | 2011-02-10 |
US20070244099A1 (en) | 2007-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20040780A1 (es) | Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion | |
PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
PE20121157A1 (es) | Compuestos heterociclicos como inhibidores de proteasas serinas | |
PE20030762A1 (es) | Compuestos heterociclicos como antagonistas nk1 | |
PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
PE20050132A1 (es) | Piperazinas heterociclicas sustituidas | |
PE20020061A1 (es) | Fenil sulfamoil carboxamidas sustituidas | |
AR053109A1 (es) | DERIVADOS DE PIPERIDINA Y PIPERAZINA, UN METODO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR DE QUIMIOQUINA CCR2. | |
PE20060150A1 (es) | Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion | |
PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
PE20040687A1 (es) | Quinolinas sustituidas como antagonistas del receptor ccr5 | |
PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
PE20050874A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
PE20060186A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparacion asi como su uso como medicamento | |
PE20040647A1 (es) | Inhibidores de cinasas de tirosina | |
PE20121526A1 (es) | Compuestos policiclicos heterociclicos como inhibidores del virus de la hepatitis c | |
PE20130647A1 (es) | Indoles | |
PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
AR057107A2 (es) | Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos | |
AR076860A1 (es) | Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
AR076859A1 (es) | Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
PE20080345A1 (es) | Derivados de piperazina como agonistas del receptor de gpr38 | |
PE20080136A1 (es) | Arilsulfonamidas sustituidas como agentes antivirales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |